^
Association details:
Biomarker:No biomarker
Cancer:Breast Cancer
Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Excerpt:
Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer....Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate.
Secondary therapy:
capecitabine; paclitaxel
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
Avastin is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of...Metastatic breast cancer, with paclitaxel for treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer.
Secondary therapy:
paclitaxel